{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06056596",
            "orgStudyIdInfo": {
                "id": "2022-1223"
            },
            "secondaryIdInfos": [
                {
                    "id": "SMPH/OPHTHAL&VIS SCI/FPRC",
                    "type": "OTHER",
                    "domain": "UW Madison"
                },
                {
                    "id": "Protocol Version 1/29/2024",
                    "type": "OTHER",
                    "domain": "UW Madison"
                }
            ],
            "organization": {
                "fullName": "University of Wisconsin, Madison",
                "class": "OTHER"
            },
            "briefTitle": "Lamivudine and Plasma Markers of Inflammation in Retinal Detachment",
            "officialTitle": "Intra-ocular Penetration of Oral Lamivudine and Measurement of Systemic Inflammatory Markers in Patients Undergoing Rhegmatogenous Retinal Detachment Surgery",
            "therapeuticArea": [
                "Ophthalmology"
            ],
            "study": "lamivudine-and-plasma-markers-of-inflammation-in-retinal-detachment"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-01-30",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-08",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-08",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-08-01",
            "studyFirstSubmitQcDate": "2023-09-20",
            "studyFirstPostDateStruct": {
                "date": "2023-09-28",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-14",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-16",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "University of Wisconsin, Madison",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": true
        },
        "descriptionModule": {
            "briefSummary": "The goal of this clinical trial is to test whether an oral medication (lamivudine) enters the eye and reduces blood markers of inflammation in people who undergo retinal detachment surgery (pars plana vitrectomy).\n\nParticipants will take the study medication or placebo, and the researchers will measure blood markers of inflammation before and after surgery. The researchers will also measure the amount of medication in the blood and fluid inside the participant's eye (which is collected during surgery).",
            "detailedDescription": "Lamivudine is an anti-viral medication that has intrinsic anti-inflammatory properties that could be useful in the treatment of vitreoretinal disease. It is not known whether lamivudine enters the eye after oral administration. The purpose of this study is to measure the intra-ocular concentration of lamivudine after oral administration in participants that require pars plana vitrectomy surgery for repair of rhegmatogenous retinal detachment. Participants undergoing retinal detachment surgery will receive oral lamivudine for three days prior to surgery; lamivudine will be measured intra-operatively (vitreous and aqueous humor) and pre-operatively (plasma). Plasma markers of inflammation will be measured before and after surgery."
        },
        "conditionsModule": {
            "conditions": [
                "Retinal Detachment",
                "Rhegmatogenous Retinal Detachment"
            ],
            "keywords": [
                "vitrectomy surgery"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "EARLY_PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "SINGLE",
                    "whoMasked": [
                        "PARTICIPANT"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 20,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Lamivudine",
                    "type": "EXPERIMENTAL",
                    "description": "Lamivudine 300mg PO once daily for three days",
                    "interventionNames": [
                        "Drug: Lamivudine 300 MG"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Placebo once daily for three days",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Lamivudine 300 MG",
                    "description": "Drug to be taken once daily for three days (two days prior to surgery and on the morning of surgery)",
                    "armGroupLabels": [
                        "Lamivudine"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Dose to be taken once daily for three days (two days prior to surgery and on the morning of surgery)",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Plasma concentration of lamivudine after oral administration",
                    "description": "Mean concentration of lamivudine in plasma",
                    "timeFrame": "Pre-operative"
                },
                {
                    "measure": "Intra-ocular concentration of lamivudine after oral administration",
                    "description": "Mean concentration of lamivudine in vitreous and aqueous humor",
                    "timeFrame": "Intra-operatively"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change in erythrocyte sedimentation rate (millimeter per hour)",
                    "description": "Mean concentration of inflammatory markers will in part be measured by erythrocyte sedimentation rate.",
                    "timeFrame": "Pre-operative to one week post-operative"
                },
                {
                    "measure": "Change in C-reactive protein (milligrams per liter)",
                    "description": "Mean concentration of inflammatory markers will in part be measured by C-reactive protein.",
                    "timeFrame": "Pre-operative to one week post-operative"
                },
                {
                    "measure": "Change in concentration of inflammatory markers (picogram per milliliter)",
                    "description": "Mean concentration of inflammatory markers will in part be measured by tumor necrosis factor alpha, interleukin (IL)-18, IL-1 beta, IL-6, IL-10, MCP-1, MIP-1 alpha, GM-CSF in picograms per milliliter.",
                    "timeFrame": "Pre-operative to one week post-operative"
                },
                {
                    "measure": "Change in concentration of inflammatory markers (micrograms per milliliter)",
                    "description": "Mean concentration of inflammatory markers will in part be measured by interferon (IFN) alpha, IFN beta, IFN gamma in micrograms per milliliter)",
                    "timeFrame": "Pre-operative to one week post-operative"
                },
                {
                    "measure": "Change in concentration of soluble IL-2 receptor alpha (Units per milliliter)",
                    "description": "Mean concentration of inflammatory markers will in part be measured by soluble IL-2 receptor alpha in Units per milliliter.",
                    "timeFrame": "Pre-operative to one week post-operative"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \u2265 18 or \u2264 75 years\n* Patients with rhegmatogenous retinal detachment that require vitrectomy surgery\n\nExclusion Criteria:\n\n* Previous pars plana vitrectomy in the affected eye\n* Positive for Hepatitis B surface antigen or HIV antibodies, or history of Hepatitis B/HIV\n* Pregnant or breast-feeding\n* Liver disease or abnormal AST/ALT\n* Renal impairment (Creatinine clearance \\< 50)\n* Diabetes with current use of insulin\n* Anemia (Hemoglobin \\<13.2 g/dL (male) or \\< 11.6 g/dL (female))\n* Unwilling to hold concurrent use of sorbitol or sorbitol-containing medications or products while taking study medication(including, but not limited to: blackberries, raspberries, strawberries, stone fruits, apples, avocados, sugar-free items such as chewing gum, hard candies, snack bars, frozen desserts, and chocolates, liquid and capsule/caplet analgesics, cough/cold/flu syrup, liquid and capsule/caplet pseudoephedrine, chewable antacid tablets, liquid and capsule allergy medications, motion sickness and nausea medications)\n* Current use of trimethoprim-sulfamethoxazole\n* Pancreatitis or history of pancreatitis\n* Uncontrolled blood pressure (\\> 160 mm Hg systolic or \\>100 mm Hg diastolic) within the last 3 months, or current use of more than one anti-hypertensive medication\n* History of stroke, myocardial infarction, or congestive heart failure\n* Current vitreous hemorrhage that obscures view of retinal details\n* Patients with a shallow anterior chamber or in whom anterior chamber paracentesis is considered unsafe",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "75 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Angie Adler",
                    "role": "CONTACT",
                    "phone": "608-265-7557",
                    "email": "amadler1@wisc.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Michael Altaweel, MD",
                    "affiliation": "University of Wisconsin, Madison",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Wisconsin",
                    "status": "RECRUITING",
                    "city": "Madison",
                    "state": "Wisconsin",
                    "zip": "53705",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Angie Adler",
                            "role": "CONTACT",
                            "phone": "608-265-7557",
                            "email": "amadler1@wisc.edu"
                        },
                        {
                            "name": "Michael Altaweel, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.07305,
                        "lon": -89.40123
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000012163",
                    "term": "Retinal Detachment"
                },
                {
                    "id": "D000004213",
                    "term": "Dissociative Disorders"
                }
            ],
            "ancestors": [
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                },
                {
                    "id": "D000012164",
                    "term": "Retinal Diseases"
                },
                {
                    "id": "D000005128",
                    "term": "Eye Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10293",
                    "name": "Inflammation",
                    "relevance": "LOW"
                },
                {
                    "id": "M14998",
                    "name": "Retinal Detachment",
                    "asFound": "Retinal Detachment",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18361",
                    "name": "Eye Injuries, Penetrating",
                    "relevance": "LOW"
                },
                {
                    "id": "M7394",
                    "name": "Dissociative Disorders",
                    "asFound": "Detachment",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6515",
                    "name": "Conversion Disorder",
                    "relevance": "LOW"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14999",
                    "name": "Retinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8271",
                    "name": "Eye Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T1568",
                    "name": "Conversion Disorder",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC11",
                    "name": "Eye Diseases"
                },
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BC26",
                    "name": "Wounds and Injuries"
                },
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000019259",
                    "term": "Lamivudine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000018894",
                    "term": "Reverse Transcriptase Inhibitors"
                },
                {
                    "id": "D000019384",
                    "term": "Nucleic Acid Synthesis Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000998",
                    "term": "Antiviral Agents"
                },
                {
                    "id": "D000000890",
                    "term": "Anti-Infective Agents"
                },
                {
                    "id": "D000019380",
                    "term": "Anti-HIV Agents"
                },
                {
                    "id": "D000044966",
                    "term": "Anti-Retroviral Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M21243",
                    "name": "Lamivudine",
                    "asFound": "Students",
                    "relevance": "HIGH"
                },
                {
                    "id": "M20935",
                    "name": "Reverse Transcriptase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M4314",
                    "name": "Antiviral Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4214",
                    "name": "Anti-Infective Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M21350",
                    "name": "Anti-HIV Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M25428",
                    "name": "Anti-Retroviral Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}